Dorsomorphin, a Selective Small Molecule Inhibitor of BMP Signaling, Promotes Cardiomyogenesis in Embryonic Stem Cells
2008

Dorsomorphin Promotes Heart Cell Development from Stem Cells

publication 10 minutes Evidence: high

Author Information

Author(s): Hao Jijun, Daleo Marie A., Murphy Clare K., Yu Paul B., Ho Joshua N., Hu Jianyong, Peterson Randall T., Hatzopoulos Antonis K., Hong Charles C.

Primary Institution: Vanderbilt University School of Medicine

Hypothesis

Can dorsomorphin, a BMP signaling inhibitor, enhance cardiomyogenesis in embryonic stem cells?

Conclusion

Dorsomorphin significantly increases the differentiation of embryonic stem cells into cardiomyocytes while reducing other cell types.

Supporting Evidence

  • Dorsomorphin treatment increased the yield of beating cardiomyocytes by at least 20 fold.
  • Cardiac markers Nkx2.5 and Myh6 showed significant increases in expression with dorsomorphin treatment.
  • Dorsomorphin treatment limited to the first 24 hours was sufficient for robust cardiac induction.

Takeaway

Dorsomorphin helps stem cells turn into heart cells better than before, but it makes it harder for them to become other types of cells.

Methodology

Mouse embryonic stem cells were treated with dorsomorphin to assess its effects on cardiomyocyte differentiation.

Potential Biases

Potential off-target effects of dorsomorphin on other signaling pathways were not fully explored.

Limitations

The study primarily focuses on mouse embryonic stem cells, which may not fully represent human stem cell behavior.

Participant Demographics

Mouse embryonic stem cells were used in the study.

Statistical Information

P-Value

p=0.0013

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0002904

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication